In this post-hoc analysis of the DELIGHT trial [13], we therefore evaluated the effects of the SGLT2 inhibitor dapagliflozin, with and without the dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin compared to placebo, on markers of erythropoiesis, iron metabolism, and inflammation in patients with type 2 diabetes and CKD. Here, SLC5A2 is linked to type 2 diabetes mellitus.